Tango Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Tango Therapeutics, Inc. (TNGX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $7.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $5.19M, a 367.75% increase year-over-year.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.30M.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$350.00K, a 139.37% decline year-over-year.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.65M, a 33.33% increase year-over-year.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.76M.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$370.00K, a 116.63% decline from fiscal 2023.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.23M, a 8.22% increase from fiscal 2022.
- Tango Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $2.06M, a 34.92% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $7.49M 10-Q · filed 2026-08-11 | $7.14M derived: sum of 3 quarters · filed 2026-08-11 | $8.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-13 | $1.95M derived: sum of 2 quarters · filed 2026-05-13 | $3.60M derived: sum of 3 quarters · filed 2026-05-13 | $4.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.30M derived: sum of 2 quarters · filed 2026-03-05 | $2.41M derived: sum of 3 quarters · filed 2026-08-11 | $1.76M 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.76M derived: sum of 2 quarters · filed 2026-08-11 | $2.11M 10-Q · filed 2025-11-04 | $3.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $461.00K 10-Q · filed 2026-08-11 | $1.35M derived: sum of 3 quarters · filed 2026-08-11 | $2.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$649.00K 10-Q · filed 2026-05-13 | $240.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.48M derived: sum of 3 quarters · filed 2026-05-13 | -$659.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $2.13M derived: sum of 2 quarters · filed 2026-03-05 | -$10.00K derived: sum of 3 quarters · filed 2026-03-05 | -$370.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$899.00K derived: sum of 2 quarters · filed 2025-11-04 | -$1.26M 10-Q · filed 2025-11-04 | -$2.62M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$2.50M 10-Q · filed 2025-08-05 | -$3.85M derived: sum of 3 quarters · filed 2026-03-05 | -$2.73M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | -$360.00K 10-Q · filed 2025-05-12 | -$1.72M derived: sum of 2 quarters · filed 2026-03-05 | -$597.00K derived: sum of 3 quarters · filed 2026-03-05 | -$918.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | -$1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$237.00K derived: sum of 2 quarters · filed 2026-03-05 | -$558.00K derived: sum of 3 quarters · filed 2026-03-05 | $2.23M 10-K · filed 2026-03-05 |
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $799.00K derived: sum of 2 quarters · filed 2024-11-06 | $3.58M 10-Q · filed 2024-11-06 | $4.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$321.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.46M 10-Q · filed 2024-08-07 | $3.22M derived: sum of 3 quarters · filed 2025-02-27 | -$8.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.78M 10-Q · filed 2024-05-08 | $3.54M derived: sum of 2 quarters · filed 2025-02-27 | -$7.81M derived: sum of 3 quarters · filed 2025-02-27 | $1.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$10.59M derived: sum of 2 quarters · filed 2025-02-27 | -$1.63M derived: sum of 3 quarters · filed 2025-02-27 | $2.06M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$11.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$2.39M derived: sum of 2 quarters · filed 2023-11-08 | $1.30M 10-Q · filed 2023-11-08 | $1.24M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $12.65M 10-Q · filed 2023-08-07 | $12.58M derived: sum of 3 quarters · filed 2023-08-07 | $15.41M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $3.69M 10-Q · filed 2023-05-09 | $3.62M derived: sum of 2 quarters · filed 2023-05-09 | $6.45M derived: sum of 3 quarters · filed 2023-05-09 | $6.71M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $2.76M derived: sum of 2 quarters · filed 2023-03-27 | $3.03M derived: sum of 3 quarters · filed 2023-03-27 | $3.16M 10-K · filed 2023-03-27 |
| 2021-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.09M derived: sum of 2 quarters · filed 2022-11-10 | $3.22M 10-Q · filed 2022-11-10 | $3.72M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $395.00K 10-Q · filed 2022-08-10 | $897.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $132.00K 10-Q · filed 2022-05-11 | $634.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $502.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $81.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | -$421.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |